Research elucidating the pathogenesis of systemic lupus erythematosus (SLE) has defined
two critical families of mediators, type I interferon (IFN-I) and autoantibodies targeting nucleic …

The past few years have provided important insights into the genetic architecture of systemic
autoimmunity through aggregation of findings from genome-wide association studies …

Systemic autoimmune rheumatic diseases (SARDs) exhibit extensive heterogeneity in
clinical presentation, disease course, and treatment response. Therefore, precision …

Traditional classification of genetic diseases as monogenic and polygenic has lagged far
behind scientific progress. In this opinion article, we propose and define a new terminology …

Systemic lupus erythematosus (SLE) is a polygenic chronic autoimmune disease leading to
multiple organ damage. A large heritability of up to 66% is estimated in SLE, with roughly …

Systemic lupus erythematosus (SLE) is a prime example of how the interplay between
genetic and environmental factors can trigger systemic autoimmunity, particularly in young …

Therapeutic success in treating patients with systemic lupus erythematosus (SLE) is limited
by the multivariate disease etiology, multi-organ presentation, systemic involvement, and …

Objective Systemic inflammatory autoimmune diseases (SIADs) such as systemic lupus
erythematosus (SLE), primary Sjögren disease (pSS), and idiopathic inflammatory …

Systemic lupus erythematosus (SLE) is a rare autoimmune/inflammatory disease with
significant morbidity and mortality. Approximately 15–20% of SLE patients develop the …

This viewpoint article on a forecast of clinically meaningful changes in the management of
systemic lupus erythematosus (SLE) in the next 10 years is based on a review of the current …